Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 831

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 831
---
 than 15 mergers and acquisition transactions
of companies as both buyer and seller and has handled large-scale licensing transactions with fortune 50 companies. Mr. Knuettel
is also a board member at Etheros Pharmaceuticals Corp. since 2023. Mr. Knuettel received his BA with honors in Economics from
Tufts University and holds an MBA in Finance and Entrepreneurial Management from The Wharton School at the University of Pennsylvania.

82 

Eric
Lang has served as our Chief Medical Officer since May 2023. Prior to that, from September 2018 to May 2023, Dr.
Lang served at Nevakar Inc, initially as Vice President of Clinical Development and later as its Chief Medical Officer. From January
2018 to September 2018, Dr. Lang served as the Chief Medical Officer at Entera Bio Ltd. (Nasdaq: ENTX). From February 2012 to
November 2017, he served at Covance (now Labcorp Drug Development), heading an international team that assisted smaller biotech
companies in moving their programs through the various phases of pre-clinical and clinical development. From August 2010 to January
2012, Dr. Lang served at Grunenthal USA, Inc. as their head of clinical development. Prior to that, Dr. Lang led the clinical
development team at Javelin Pharmaceuticals, Inc. from October 2008 to August 2010, which was acquired by Hospira (now Pfizer
Inc.) in 2010. Dr. Lang worked for Novartis Consumer Health from October 2006 to October 2008 and he began his career with Johnson &
Johnson (NYSE: JNJ) where he worked from 1999 to 2006. In addition, Dr. Lang serves on several boards including with Cytogel Pharmaceuticals
and the NIH/NINDS EPPIC initiative.  Dr. Lang is an Anesthesiologist and Pain Management Specialist with over 26 years of
experience in the pharmaceutical industry. During his pharmaceutical career, he has had both broad-based drug and device development
expertise in a variety of therapeutic areas. Dr. Lang has experience in designing development programs from early translational
stages through phase III including the successful filing of several recent INDs and NDAs. He has experience with regulatory interactions
and negotiations with FDA and various European and Asian Authorities. Dr. Lang received his Doctor of Medicine from Ben-Gurion
University of the Nege